RET and non-small cell lung carcinoma: However, it remains to be seen if certain subsets of patients may derive some benefits from the use of TKIs, including axitinib, as reported for other TKIs in patients with genomic abnormalities such as EGFR mutations [25-27], crizotinib in ALK-positive NSCLC [28], or in preclinical studies involving RET proto-oncogene rearrangements [29,30].